Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS	4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS	5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS	6	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS	7	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS	8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS	9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	12	JAN 17	IPC 8 in the WPI family of databases including WPIFV

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:48:37 ON 24 JAN 2006

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:48:47 ON 24 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JAN 2006 HIGHEST RN 872490-64-7
DICTIONARY FILE UPDATES: 23 JAN 2006 HIGHEST RN 872490-64-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10646495.str



chain nodes :
10 11 13 14 17
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
10-11 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 13-14

G1:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

```
L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1                STR
```




```
G1 O,S


Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 07:49:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     5769 TO ITERATE

 34.7% PROCESSED     2000 ITERATIONS                                 5 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       110826 TO   119934
PROJECTED ANSWERS:              61 TO      515

L2             5 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 07:49:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   116322 TO ITERATE

100.0% PROCESSED   116322 ITERATIONS                             213 ANSWERS
SEARCH TIME: 00.00.01

L3           213 SEA SSS FUL L1

=> s l3 and caplus/lc
      49412419 CAPLUS/LC
L4          213 L3 AND CAPLUS/LC

=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               171.70     171.91

FILE 'CAPLUS' ENTERED AT 07:49:36 ON 24 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 24 Jan 2006 VOL 144 ISS 5
FILE LAST UPDATED: 23 Jan 2006 (20060123/ED)

=> s l4
L5 13 L4

=> d ibib abs hitstr 1-13

L5 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:514300 CAPLUS
DOCUMENT NUMBER: 143:221964
TITLE: Effect of Hesperadin small molecule on breast and prostate cancer cell lines
AUTHOR(S): Ladygina, N. G.; Lacis, R. V.; Yen, T.
CORPORATE SOURCE: Russian State Medical University, Moscow, 117437, Russia
SOURCE: Biomeditsinskaya Khimiya (2005), 51(2), 170-176
CODEN: BKIHA8
PUBLISHER: NII Biomeditsinskoi Khimii
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB Aurora B, which is important for cell division control, is highly expressed in large number of cancer cell lines. Hesperadin, a prototype of a pharmacol. agent, is a small mol. inhibitor of catalytic activity of Aurora B. In present work the authors investigate effect of hesperadin on breast - MCF7 and prostate adenocarcinoma - PC3, cancer cell lines. Hesperadin treatment resulted in inhibition of cell proliferation due to appearance of multiple mitotic defects caused by Aurora B activity reduction and elimination of checkpoint proteins - such as hBUBR1 and CENP-E - from kinotochores of mitotic chromosomes.

IT 422513-13-1, Hesperadin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of hesperadin on breast and prostate cancer cell lines)
RN 422513-13-1 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L5 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:424380 CAPLUS
DOCUMENT NUMBER: 143:111468
TITLE: Mechanism of Aurora B activation by INCENP and inhibition by hesperadin
AUTHOR(S): Sessa, Fabio; Mapelli, Marina; Ciferri, Claudio; Tarricone, Cataldo; Areces, Liliana B.; Schneider, Thomas R.; Stukenberg, P. Todd; Musacchio, Andrea
CORPORATE SOURCE: Department of Experimental Oncology, European Institute of Oncology, Milan, 20141, Italy
SOURCE: Molecular Cell (2005), 18(3), 379-391
CODEN: MOCEFL; ISSN: 1097-2765
PUBLISHER: Cell Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Aurora family serine/threonine kinases control mitotic progression, and their deregulation is implicated in tumorigenesis. Aurora A and Aurora B, the best-characterized members of mammalian Aurora kinases, are .apprx.60% identical but bind to unrelated activating subunits. The structure of the complex of Aurora A with the TPX2 activator has been reported previously. Here, we report the crystal structure of Aurora B in complex with the IN-box segment of the inner centromere protein (INCENP) activator and with the small mol. inhibitor Hesperadin. The Aurora B:INCENP complex is remarkably different from the Aurora A:TPX2 complex. INCENP forms a crown around the small lobe of Aurora B and induces the active conformation of the T loop allosterically. The structure represents an intermediate state of activation of Aurora B in which the Aurora B C-terminal segment stabilizes an open conformation of the catalytic cleft, and a critical ion pair in the kinase active site is impaired. Phosphorylation of two serines in the carboxyl terminus of INCENP generates the fully active kinase.

IT 422513-13-1, Hesperadin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(crystal structure and mechanism of Aurora B activation by INCENP and inhibition by hesperadin)
RN 422513-13-1 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS

L5 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:324323 CAPLUS
DOCUMENT NUMBER: 142:367631
TITLE: Fluorescent probes for use in protein kinase inhibitor binding competition assay for screening applications
INVENTOR(S): Prokopowicz, Anthony S.; Brown, Martha Priscilla; Wildeson, Jessi Marie; Jakes, Scott; Labadia, Mark E.
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005033330	A2	20050414	WO 2004-US32253	20040930
WO 2005033330	A3	20050728		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005100978	A1	20050512	US 2004-955129	20040930
PRIORITY APPLN. INFO.:			US 2003-508539P	P 20031003

OTHER SOURCE(S): MARPAT 142:367631

AB The invention provides methods relating to a novel screening assay format that can be applied to broad members of the protein kinase gene family. More specifically, the assay was used for inhibitors of STK12 kinase domain. The assay uses a series of fluorescently labeled, active site probes described herein that can be displaced by an inhibitor agent. The Kd for the inhibitor compound is derived based on the Kd of the probe for the kinase and the dose response of the inhibitor agent. The invention also provides novel active site probes suitable for use with the screening method.

IT 849339-49-7
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(fluorescent probe; fluorescent probes for use in protein kinase inhibitor binding competition assay for screening applications)
RN 849339-49-7 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-5-carboxamide, N-[6-[[4-[[[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]benzoyl]amino]hexyl]-2',7'-difluoro-3',6'-dihydroxy-3-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L5 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L5 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:29195 CAPLUS
DOCUMENT NUMBER: 142:127561
TITLE: Use of aurora kinase inhibitors for reducing the resistance of cancer cells to mitotic spindle assembly inhibitors
INVENTOR(S): Anand, Shubha; Venkitaraman, Ashok
PATENT ASSIGNEE(S): Cambridge University Technical Services Ltd., UK
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005002571	A1	20050113	WO 2003-GB2862	20030703

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: WO 2003-GB2862 20030703

AB The invention discloses the use of anticancer agents that inhibit mitotic spindle assembly in target cells, including taxanes such as paclitaxel, and in particular to methods and means for predicting and/or reducing the resistance of cancer cells to such agents. Over-expression of aurora kinases, such as Aurora A, mediates resistance to such anti-cancer agents and the resistance of a cancer cell may be reduced by inhibiting aurora kinases and/or predicted by measuring the expression or activity of aurora kinases within the cell.

IT 422513-13-1, Hesperadin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aurora kinase inhibitors for reducing resistance of cancer cells to mitotic spindle assembly inhibitors)

RN 422513-13-1 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L5 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:433750 CAPLUS
DOCUMENT NUMBER: 141:7131
TITLE: Preparation of quinazolines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for the treatment of cancer
INVENTOR(S): Barnett, Stanley F.; Defeo-Jones, Deborah D.; Hartman, George D.; Huber, Hans E.; Stirdivant, Steven M.; Heimbrook, David C.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 121 pp., which
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004102360	A1	20040527	US 2003-678565		20031003
PRIORITY APPLN. INFO.:			US 2002-422312P	P	20021030
			US 2003-460911P	P	20030407

OTHER SOURCE(S): MARPAT 141:7131
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to methods of treating cancer using a combination of at least two Akt inhibitors I [wherein Q = (un)substituted heterocyclyl, aryl; U, V, W, and X = independently CH, N; Y, Z = independently CH, N, provided that at least one of Y and Z = N; n = 0-3; p = 0-2; q = 0-4; R1, R2, R7 = independently halo, CN, OH, CHO, NO2, or (un)substituted (cyclo)alkyl(oxy), alkenyl(oxy), alkynyl(oxy), heterocyclyl(oxy), acyl, carboxy, carbamoyl(oxy), ureido, sulfamoyl, etc.; R3, R4 = independently H, (perfluoro)alkyl; or CR3R4 = cycloalkyl, heterocyclyl; and pharmaceutically acceptable salts or stereoisomers thereof] or a combination of I and a protein kinase inhibitor II [wherein G = H2, O; X = C, N, SO0-2, O; m = 0-2; n = 0-2; p = 0-6; q = 0-4; R1 = independently H, halo, or (un)substituted (cyclo)alkyl, heterocyclyl, aryl, carbamoyl, amino, acyl, sulfamoyl, carboxy, etc.; R2 = H or (un)substituted (cyclo)alkyl(oxy), amino, arylоxy, heterocyclyloxy, alkenyloxy, alkynyloxy, etc.; R5 = independently H, halo, NO2, CN, or (un)substituted alkyl, alkenyl, alkynyl, carboxy, acyl, sulfamoyl, carbamoyl, ureido, amino, etc.; and pharmaceutically acceptable salts or stereoisomers thereof], optionally in combination with a third compound Examples include syntheses for I and II and assays demonstrating Akt inhibitor activity, antitumor activity, and the synergistic effect of combinations of AKT inhibitors and/or protein kinase inhibitors on caspase 3 activity. For instance, III•HCl was prepared in an 8-step reaction sequence culminating with the cycloaddn. of 4-(2-aminoprop-2-yl)benzil and

L5 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
o-phenylenediamine using glacial acetic acid in H2O, followed by work up with chloroform and ethanolic HCl. III•HCl, a selective Akt1 and Akt2 inhibitor, demonstrated a 3.2-fold in caspase 3 activation over control compared to a 1.2-fold increase for a protein kinase inhibitor. Combination treatment produced a 9-fold increase in caspase 3 activation.

IT **661468-36-6P 661468-78-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antitumor agent; preparation of quinazolines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for treatment of cancer)

RN 661468-36-6 CAPLUS
CN 1H-Indole-2-carboxamide, 7-[(methylsulfonyl)amino]-3-(4-morpholinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 661468-78-6 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(methylsulfonyl)amino]-3-(4-morpholinylsulfonyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:165370 CAPLUS
DOCUMENT NUMBER: 140:372499
TITLE: Correcting improper chromosome-spindle attachments during cell division
AUTHOR(S): Lampson, Michael A.; Renduchitala, Kishore; Khodjakov, Alexey; Kapoor, Tarun M.
CORPORATE SOURCE: Laboratory of Chemistry and Cell Biology, Rockefeller University, New York, NY, 10021, USA
SOURCE: Nature Cell Biology (2004), 6(3), 232-237
CODEN: NCBIFN; ISSN: 1465-7392
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB For accurate segregation of chromosomes during cell division, microtubule fibers must attach sister kinetochores to opposite poles of the mitotic spindle (bi-orientation). Aurora kinases are linked to oncogenesis and have been implicated in the regulation of chromosome-microtubule attachments. Although loss of Aurora kinase activity causes an accumulation of mal-orientated chromosomes in dividing cells, it is not known how the active kinase corrects improper chromosome attachments. The use of reversible small-mol. inhibitors allows activation of protein function in living vertebrate cells with temporal control. Here we show that by removal of small-mol. inhibitors, controlled activation of Aurora kinase during mitosis can correct chromosome attachment errors by selective disassembly of kinetochore-microtubule fibers, rather than by alternative mechanisms involving initial release of microtubules from either kinetochores or spindle poles. Observation of chromosomes and microtubule dynamics with real-time high-resolution microscopy showed that mal-orientated, but not bi-orientated, chromosomes move to the spindle pole as both kinetochore-microtubule fibers shorten, followed by alignment at the metaphase plate. Our results provide direct evidence for a mechanism required for the maintenance of genome integrity during cell division.

IT **422513-13-1**, Hesperadin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(aurora kinase inhibitor; improper chromosome-spindle attachments during cell division corrected after removal of Aurora kinase inhibitors)

RN 422513-13-1 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L5 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:143099 CAPLUS
DOCUMENT NUMBER: 140:199202
TITLE: Preparation of substituted sulfonyl indoles as novel tyrosine kinase inhibitors
INVENTOR(S): Dinsmore, Christopher J.; Beshore, Douglas C.; Bergman, Jeffrey M.; Lindsley, Craig W.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014851	A2	20040219	WO 2003-US24643	20030805
WO 2004014851	A3	20040902		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2494962	AA	20040219	CA 2003-2494962	20030805
EP 1534695	A2	20050601	EP 2003-784961	20030805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005538132	T2	20051215	JP 2004-527799	20030805
US 2005261496	A1	20051124	US 2005-523285	20050203
PRIORITY APPLN. INFO.:			US 2002-402478P	P 20020809
			WO 2003-US24643	W 20030805

OTHER SOURCE(S): MARPAT 140:199202
GI



AB Title compds. I [R5 = H, halo, NO2, CN, COR4, -C.tplbond.CR4, etc.; R4 = H, alkyl, cycloalkyl, aryl, heterocycle, CF3, alkenyl, or alkynyl; R2 = H,

L5 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(un)substituted alkyl, N(R4)2, OR4, (un)substituted-aryl or -cycloalkyl; R1 = H, halo, (CRa2)nOR4, (CRa2)nCO2R4, CON(R4)(CRa2)nN(R4)2, etc.; Y = heterocycle or optional double bond; m = 0-6, n = independently 0-6, p = 0-4) and their pharmaceutically acceptable salts are prepd. and disclosed
as tyrosine kinase inhibitors. Thus, II was prepd. via N-phenylsulfonylation of Et 5-chloro-1H-indole-2-carboxylate with subsequent sulfonation, chlorination to provide the 3-chlorosulfonylindole
intermediate which was substituted with morpholine and underwent ammonolysis to provide the product. The present invention relates to compds. that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. I were found to possess IC50 values of less than or equal to 100
μM in assays to det. inhibition of IFG-1R or insulin receptor kinase activity. Addnl., claims for administration with codrugs (e.g., estrogen receptor modulators, GPIIB/IIIa antagonists, or COX-2 inhibitors) to treat
or prevent cancer are disclosed.

IT **661468-36-6P 661468-78-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation and tyrosine kinase inhibition activity of
substituted sulfonyl indoles)

RN 661468-36-6 CAPLUS
CN 1H-Indole-2-carboxamide, 7-[(methylsulfonyl)amino]-3-(4-morpholinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 661468-78-6 CAPLUS
CN 1H-Indole-2-carboxamide, 5-[(methylsulfonyl)amino]-3-(4-morpholinylsulfonyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L5 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:138723 CAPLUS
DOCUMENT NUMBER: 140:193052
TITLE: Use of LCK inhibitors for treatment of immunological diseases
INVENTOR(S): Roth, Gerald Jurgen; Heckel, Armin; Walter, Rainer; Hilberg, Frank; Hauptmann, Rudolf; Ernst, Steffen; Stefanic, Martin; Colbatzky, Florian
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10237423	A1	20040219	DE 2002-10237423	20020816
CA 2495350	AA	20040304	CA 2003-2495350	20030811
WO 2004017948	A2	20040304	WO 2003-EP8890	20030811
WO 2004017948	A3	20040422		
WO 2004017948	C1	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1530466	A2	20050518	EP 2003-792292	20030811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004204458	A1	20041014	US 2003-640926	20030814

PRIORITY APPLN. INFO.:

DE 2002-10237423	A	20020816
US 2002-409204P	P	20020909
WO 2003-EP8890	W	20030811

AB The invention discloses a method for treatment of immunol. diseases or pathol. conditions which contain an immunol. component, using certain LCK inhibitors, which already are known as kinase inhibitors for therapy in oncol., optionally in combination with one or more other medications selected from NSAIDs, steroids, DMARDs, immunosuppressants, biol. response
modifiers, and antiinfectives. Also disclosed are pharmaceutical compns. which contain the LCK inhibitors as well as the other medications, and use
of LCK inhibitors for production of a pharmaceutical composition for treatment of
immunol. diseases or pathol. conditions which contain an immunol. component.

IT **422512-86-5 422512-95-6 422513-10-8 422513-13-1 422513-40-4 422513-50-6 422513-52-8 422514-67-8 422515-40-0 422516-96-9**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

L5 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(Biological study); USES (Uses)
(LCK inhibitors for treatment of immunol. diseases, and use with other agents)

RN 422512-86-5 CAPLUS
CN 1-Piperidineacetamide, N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422512-95-6 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-3-[[[4-[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-10-8 CAPLUS
CN Methanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-13-1 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-

L5 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-40-4 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-50-6 CAPLUS
CN Benzenesulfonamide, 4-amino-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-52-8 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[[4-[[2-(dimethylamino)ethyl](methylsulfonyl)amino]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L5 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L5 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 422514-67-8 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-3-[[[4-[[4-(3-aminopropyl)-1-piperidinyl]methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-40-0 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-96-9 CAPLUS
CN 1-Piperidineacetamide, N-[4-[[(Z)-(1,2-dihydro-5-[methyl(phenylsulfonyl)amino]-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L5 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:339131 CAPLUS
DOCUMENT NUMBER: 139:162558
TITLE: The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint
AUTHOR(S): Hauf, Silke; Cole, Richard W.; LaTerra, Sabrina; Zimmer, Christine; Schnapp, Gisela; Walter, Rainer; Heckel, Armin; van Meel, Jacques; Rieder, Conly L.; Peters, Jan-Michael
CORPORATE SOURCE: Research Institute of Molecular Pathology, Vienna, 1030, Austria
SOURCE: Journal of Cell Biology (2003), 161(2), 281-294
CODEN: JCLBA3; ISSN: 0021-9525
PUBLISHER: Rockefeller University Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The proper segregation of sister chromatids in mitosis depends on bipolar attachment of all chromosomes to the mitotic spindle. We have identified the small mol. Hesperadin as an inhibitor of chromosome alignment and segregation. Our data imply that Hesperadin causes this phenotype by inhibiting the function of the mitotic kinase Aurora B. Mammalian cells treated with Hesperadin enter anaphase in the presence of numerous monooriented chromosomes, many of which may have both sister kinetochores attached to one spindle pole (syntelic attachment). Hesperadin also causes cells arrested by taxol or monastrol to enter anaphase within <1 h, whereas cells in nocodazole stay arrested for 3-5 h. Together, our data suggest that Aurora B is required to generate unattached kinetochores on monooriented chromosomes, which in turn could promote bipolar attachment as well as maintain checkpoint signaling.

IT **422513-13-1**, Hesperadin
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hesperadine; Hesperadin inhibition shows role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining spindle assembly checkpoint)

RN 422513-13-1 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:353428 CAPLUS
DOCUMENT NUMBER: 136:369603
TITLE: Preparation of (sulfonylamino)(aminomethylidene)indolinones as cell proliferation inhibitors.
INVENTOR(S): Walter, Rainer; Heckel, Armin; Roth, Gerald Juergen; Kley, Joerg; Schnapp, Gisela; Lenter, Martin; Van Meel, Jacobus Constantinus Antonius; Spevak, Walter; Weyer-Czernilofsky, Ulrike
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036564	A1	20020510	WO 2001-EP12523	20011030
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10054019	A1	20020523	DE 2000-10054019	20001101
AU 2002015980	A5	20020515	AU 2002-15980	20011030
EP 1341760	A1	20030910	EP 2001-992699	20011030
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004513113	T2	20040430	JP 2002-539324	20011030
US 2003069299	A1	20030410	US 2001-2939	20011101
US 6638965	B2	20031028		
US 2004044222	A1	20040304	US 2003-646423	20030822
US 2004044053	A1	20040304	US 2003-646495	20030822

PRIORITY APPLN. INFO.: DE 2000-10054019 A 20001101
US 2000-251055P P 20001201
WO 2001-EP12523 W 20011030
US 2001-2939 A3 20011101

OTHER SOURCE(S): MARPAT 136:369603
GI



I

AB Title compds. [I; X = O, S; R1 = H, alkoxycarbonyl, alkanoyl; R2 = (substituted) alkyl, alkenyl, Ph, heteroaryl, cycloalkyl, naphthyl, etc.; R3 = H, alkyl; R4 = (substituted) Ph, naphthyl, heteroaryl; R5, R6 = H, alkyl], were prepared Thus, 1-acetyl-3-(1-ethoxy-1-phenylmethylidene)-5-(N-acetyl-N-phenylsulfonylamino)-2-indolinone (preparation given) and 4-[N-acetyl-N-(2-trifluoracetylaminoethyl)amino]aniline (preparation given) were heated in DMF for 6 h at 120° to give 49% (Z)-3-[1-[4-[N-acetyl-N-(2-aminoethyl)amino]phenylamino]-1-phenylmethylidene]-5-phenylsulfonylamino-2-indolinone. Tested I inhibited proliferation of leiomyosarcoma SK-UT-1B cells in mice at <0.01 μM-1.0 μM.

IT 422512-55-8P 422512-58-1P 422512-61-6P
422512-65-0P 422512-68-3P 422512-71-8P
422512-74-1P 422512-77-4P 422512-80-9P
422512-83-2P 422512-86-5P 422512-89-8P
422512-92-3P 422512-95-6P 422512-98-9P
422513-01-7P 422513-04-0P 422513-07-3P
422513-10-8P 422513-13-1P 422513-16-4P
422513-19-7P 422513-22-2P 422513-25-5P
422513-28-8P 422513-31-3P 422513-34-6P
422513-37-9P 422513-40-4P 422513-43-7P
422513-46-0P 422513-48-2P 422513-50-6P
422513-52-8P 422513-54-0P 422513-56-2P
422513-58-4P 422513-59-5P 422513-61-9P
422513-63-1P 422513-65-3P 422513-67-5P
422513-69-7P 422513-71-1P 422513-73-3P
422513-76-6P 422513-78-8P 422513-80-2P
422513-82-4P 422513-84-6P 422513-86-8P
422513-91-5P 422513-93-7P 422513-95-9P
422513-96-0P 422513-98-2P 422514-00-9P
422514-02-1P 422514-04-3P 422514-06-5P
422514-08-7P 422514-10-1P 422514-12-3P
422514-14-5P 422514-16-7P 422514-18-9P
422514-20-3P 422514-22-5P 422514-24-7P
422514-26-9P 422514-28-1P 422514-30-5P
422514-32-7P 422514-34-9P 422514-36-1P
422514-37-2P 422514-39-4P 422514-41-0P
422514-43-0P 422514-45-2P 422514-47-4P
422514-49-6P 422514-51-0P 422514-53-2P
422514-55-4P 422514-57-6P 422514-59-8P
422514-61-2P 422514-63-4P 422514-65-6P
422514-67-8P 422514-69-0P 422514-70-3P
422514-72-5P 422514-74-7P 422514-76-9P
422514-78-1P 422514-80-5P 422514-81-6P
422514-83-8P 422514-85-0P 422514-87-2P
422514-89-4P 422514-92-9P 422514-94-1P
422514-96-3P 422514-98-5P 422515-00-2P
422515-02-4P 422515-03-5P 422515-05-7P
422515-07-9P 422515-09-1P 422515-11-5P
422515-13-7P 422515-15-9P 422515-17-1P
422515-19-3P 422515-21-7P 422515-24-0P
422515-26-2P 422515-28-4P 422515-30-8P
422515-32-0P 422515-34-2P 422515-36-4P
422515-38-6P 422515-40-0P 422515-41-1P
422515-43-3P 422515-45-5P 422515-47-7P
422515-50-2P 422515-52-4P 422515-54-6P
422515-56-8P 422515-58-0P 422515-60-4P
422515-63-7P 422515-65-9P 422515-67-1P

422515-69-3P 422515-74-0P 422515-76-2P
422515-78-4P 422515-80-8P 422515-82-0P
422515-84-2P 422515-86-4P 422515-88-6P
422515-90-0P 422515-91-1P 422515-93-3P
422515-95-5P 422515-97-7P 422515-99-9P
422516-01-6P 422516-04-9P 422516-06-1P
422516-08-3P 422516-10-7P 422516-12-9P
422516-15-2P 422516-17-4P 422516-19-6P
422516-21-0P 422516-23-2P 422516-25-4P
422516-27-6P 422516-30-1P 422516-32-3P
422516-34-5P 422516-36-7P 422516-38-9P
422516-40-3P 422516-42-5P 422516-44-7P
422516-45-8P 422516-47-0P 422516-49-2P
422516-51-6P 422516-53-8P 422516-56-1P
422516-58-3P 422516-60-7P 422516-62-9P
422516-63-0P 422516-65-2P 422516-67-4P
422516-69-6P 422516-71-0P 422516-73-2P
422516-75-4P 422516-77-6P 422516-80-1P
422516-82-3P 422516-84-5P 422516-86-7P
422516-88-9P 422516-90-3P 422516-92-5P
422516-94-7P 422516-96-9P 422516-98-1P
422517-00-8P 422556-76-1P 422556-77-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (sulfonylamino)(aminomethylidene)indolinones as cell proliferation inhibitors)

RN 422512-55-8 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[[4-[(2-aminoethyl)(methylsulfonyl)amino]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422512-58-1 CAPLUS
CN Benzenesulfonamide, N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422512-61-6 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422512-65-0 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422512-68-3 CAPLUS
CN Acetamide, N-[4-[[(Z)-(1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422512-80-9 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[[4-[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422512-83-2 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-[methyl(methylsulfonyl)amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422512-86-5 CAPLUS
CN 1-Piperidineacetamide, N-[4-[[(Z)-(1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-



RN 422512-71-8 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl(phenylamino)methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422512-74-1 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[(4-chlorophenyl)amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422512-77-4 CAPLUS
CN Propanamide, N-[4-[[(Z)-(1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-[2-[(1-oxopropyl)amino]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422512-89-8 CAPLUS
CN Benzenemethanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422512-92-3 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[[4-[(2,6-dimethyl-1-piperidinyl)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]-3-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422512-95-6 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-3-[[[4-[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422512-98-9 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-[[methyl(phenylmethyl)amino]methyl]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-01-7 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-3-[[[4-[2-(dimethylamino)ethyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-04-0 CAPLUS
CN 3-Pyridinesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-16-4 CAPLUS
CN 2-Propanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-19-7 CAPLUS
CN 1-Naphthalenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-22-2 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-3-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-07-3 CAPLUS
CN Pyrrolidine, 1-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(3-pyridinylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-10-8 CAPLUS
CN Methanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-13-1 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-25-5 CAPLUS
CN 4-Isoxazolesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-28-8 CAPLUS
CN Cyclopropanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-31-3 CAPLUS
CN 3-Pyridinesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-34-6 CAPLUS
CN Cyclopropanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-37-9 CAPLUS
CN 1-Propanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-40-4 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-43-7 CAPLUS
CN Methanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-46-0 CAPLUS
CN Benzamide, 4-[[(Z)-(1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-48-2 CAPLUS
CN Acetamide, 2-[acetyl[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-50-6 CAPLUS
CN Benzenesulfonamide, 4-amino-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-52-8 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[[4-[[2-(dimethylamino)ethyl](methylsulfonyl)amino]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-54-0 CAPLUS
CN Propanamide, N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-56-2 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-[[2-(methylamino)ethyl](methylsulfonyl)amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-58-4 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[[4-[[2-(dimethylamino)ethyl](propylsulfonyl)amino]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-59-5 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[[4-[(butylsulfonyl)[2-

(dimethylamino)ethyl]amino]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-61-9 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-[[4-

(phenylmethyl)-1-piperazinyl]methyl]phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-63-1 CAPLUS
CN Carbamic acid, [2-[acetyl[4-[[(Z)-[1,2-dihydro-2-oxo-5-

[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]amino]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-65-3 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-(4-morpholinylmethyl)phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-67-5 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[[[4-[(2-oxo-1-piperidinyl)methyl]phenyl]amino]phenylmethylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-69-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[4-[[(Z)-[1,2-dihydro-2-oxo-5-

[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-71-1 CAPLUS
CN Benzenesulfonamide,
N-[(3Z)-3-[[[4-(formylmethylamino)phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-73-3 CAPLUS
CN Carbamic acid, [4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 422513-76-6 CAPLUS
CN Acetamide, N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-78-8 CAPLUS
CN Benzenesulfonamide,
N-[(3Z)-3-[[[4-[(ethylsulfonyl)methylamino]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-80-2 CAPLUS
CN Butanamide, N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-82-4 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-[[2-

[methyl(phenylmethyl)amino]ethyl]amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-84-6 CAPLUS
CN Benzenesulfonamide,
N-[(3Z)-3-[[[4-[[2-(dimethylamino)ethyl](methylsulfony
l)amino]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-86-8 CAPLUS
CN Acetamide, N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-
indol-3-ylidene]phenylmethyl]amino]phenyl]-N-[2-(dimethylamino)ethyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-91-5 CAPLUS
CN Acetamide, N-[2-(acetylamino)ethyl]-N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-
[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-93-7 CAPLUS
CN Propanamide, N-[2-(acetylamino)ethyl]-N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-
[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-95-9 CAPLUS
CN Acetamide,
N-[2-[[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-
indol-3-ylidene]phenylmethyl]amino]phenyl](methylsulfonyl)amino]ethyl]-N-
methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-96-0 CAPLUS

CN Acetamide,
N-[2-[[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-
indol-3-ylidene]phenylmethyl]amino]phenyl](methylsulfonyl)amino]ethyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422513-98-2 CAPLUS
CN Acetamide,
N-[2-[[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-
indol-3-ylidene]phenylmethyl]amino]phenyl](ethylsulfonyl)amino]ethyl]-N-
methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-00-9 CAPLUS
CN Benzenesulfonamide,
N-[(3Z)-3-[[(4-cyanophenyl)amino]phenylmethylene]-2,3-
dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-02-1 CAPLUS
CN Benzenesulfonamide,
N-[(3Z)-3-[[[4-[2-(dimethylamino)ethyl]phenyl]amino]ph
enylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-04-3 CAPLUS
CN Acetamide,
N-[2-[[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-
indol-3-ylidene]phenylmethyl]amino]phenyl](ethylsulfonyl)amino]ethyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-06-5 CAPLUS
CN Acetamide, N-[[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-
indol-3-ylidene]phenylmethyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-08-7 CAPLUS
CN Acetamide, N-[2-[acetyl[4-[[(Z)-[1,2-dihydro-2-oxo-5-

[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]amino
]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-10-1 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-

[(methylsulfonyl)amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-12-3 CAPLUS
CN Benzenesulfonamide,
N-[(3Z)-3-[[[4-[(ethylsulfonyl)amino]phenyl]amino]phen
ylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-14-5 CAPLUS
CN Propanamide,
N-[2-(acetylmethylamino)ethyl]-N-[4-[[(Z)-[1,2-dihydro-2-oxo-
5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-16-7 CAPLUS
CN Propanamide, N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-
indol-3-ylidene]phenylmethyl]amino]phenyl]-N-[2-
[methyl(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-18-9 CAPLUS

CN Acetamide, 2-[[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-
indol-3-ylidene]phenylmethyl]amino]phenyl]amino]-N,N-dimethyl- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.



RN 422514-20-3 CAPLUS
CN Benzenesulfonamide,
N-[(3Z)-3-[[[4-(formylamino)phenyl]amino]phenylmethyle
ne]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-22-5 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[[4-[(2,6-dimethyl-1-
piperidinyl)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-
indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-24-7 CAPLUS
CN Acetamide, N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-

indol-3-ylidene]phenylmethyl]amino]phenyl]-2-(dimethylamino)-N-methyl-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-26-9 CAPLUS
CN Benzenemethanesulfonamide, N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-

[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-[2-
(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-28-1 CAPLUS
CN Propanamide, N-[2-[[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-
3H-indol-3-ylidene]phenylmethyl]amino]phenyl]amino]ethyl]- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.



RN 422514-30-5 CAPLUS
CN Carbamic acid, [[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]methyl]propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-32-7 CAPLUS
CN Carbamic acid, butyl[[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-34-9 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-3-[[(4-methylphenyl)amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-36-1 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[[4-[(ethylmethylamino)methyl]phenyl]amino]



RN 422514-43-0 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[[4-[(2,6-dimethyl-1-piperidinyl)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]-3-methoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-45-2 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-3-methoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-47-4 CAPLUS
CN Carbamic acid, [[4-[[(Z)-[1,2-dihydro-5-[[(3-methoxyphenyl)sulfonyl]amino]-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-37-2 CAPLUS
CN Benzenemethanesulfonamide, N-[(3Z)-3-[[[4-[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-39-4 CAPLUS
CN Carbamic acid, [[4-[[(Z)-[1,2-dihydro-2-oxo-5-[[(phenylmethyl)sulfonyl]amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-41-8 CAPLUS
CN Benzenemethanesulfonamide, N-[(3Z)-3-[[[4-[(2,6-dimethyl-1-piperidinyl)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—OBu-t

RN 422514-49-6 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-3-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-51-0 CAPLUS
CN Carbamic acid, [[4-[[(Z)-[1,2-dihydro-5-[[(3-nitrophenyl)sulfonyl]amino]-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—OBu-t

RN 422514-53-2 CAPLUS
CN Benzenesulfonamide, 2-cyano-N-[(3Z)-2,3-dihydro-3-[[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-55-4 CAPLUS
CN Benzamide, 3-[[[(3Z)-2,3-dihydro-3-[[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]amino]sulfonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-61-2 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-3-[[(4-chlorophenyl)amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-63-4 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-2,3-dihydro-3-[[(4-nitrophenyl)amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-65-6 CAPLUS
CN Carbamic acid, [[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 422514-57-6 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl(phenylamino)methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-59-8 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-3-[[[4-[[2-(dimethylamino)ethyl](methylsulfonyl)amino]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-67-8 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-3-[[[4-[[4-(3-aminopropyl)-1-piperidinyl]methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-69-0 CAPLUS
CN Acetamide, N-[3-[1-[[4-[[(Z)-[5-[(ethylsulfonyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]methyl]-4-piperidinyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-70-3 CAPLUS
CN 3-Pyridinesulfonamide, N-[(3Z)-3-[[[4-[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-72-5 CAPLUS
CN Acetamide,
N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(3-pyridinylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-74-7 CAPLUS
CN 3-Pyridinesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-[methyl(methylsulfonyl)amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-76-9 CAPLUS
CN 3-Pyridinesulfonamide,
N-[(3Z)-3-[[[4-[[2-(dimethylamino)ethyl](methylsulfonyl)amino]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]-

RN 422514-81-6 CAPLUS
CN Benzamide, 4-[[(Z)-[1,2-dihydro-2-oxo-5-[(3-pyridinylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-83-8 CAPLUS
CN 3-Pyridinesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-85-0 CAPLUS
CN 3-Pyridinesulfonamide, N-[(3Z)-3-[[[3-chloro-4-[[2-(dimethylamino)ethyl](methylsulfonyl)amino]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-87-2 CAPLUS
CN 3-Pyridinesulfonamide, N-[(3Z)-3-[[[3-amino-4-[[2-

(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-78-1 CAPLUS
CN 3-Pyridinesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-(1H-imidazol-2-yl)phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-80-5 CAPLUS
CN 3-Pyridinesulfonamide,
N-[(3Z)-2,3-dihydro-3-[[[4-(1-methyl-1H-imidazol-2-yl)phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



{dimethylamino)ethyl](methylsulfonyl)amino]phenyl}amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-89-4 CAPLUS
CN 2-Pyridinesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-92-9 CAPLUS
CN Acetamide,
N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(2-pyridinylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-[2-[methyl(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-94-1 CAPLUS
CN Propanamide,
N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(2-pyridinylsulfonyl)amino]-

3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-[3-(dimethylamino)propyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-96-3 CAPLUS
CN 2-Pyridinesulfonamide,
N-[(3Z)-3-[[[4-[[3-(dimethylamino)propyl](methylsul

fonyl)amino]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422514-98-5 CAPLUS
CN 2-Pyridinesulfonamide,
N-[(3Z)-3-[[[4-[[3-(dimethylamino)propyl](propylsul

fonyl)amino]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-00-2 CAPLUS
CN 2-Pyridinesulfonamide,
N-[(3Z)-3-[[[4-[[2-(dimethylamino)ethyl](methylsulf

onyl)amino]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-02-4 CAPLUS
CN 1-Piperidineacetamide, N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(2-
pyridinylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-
methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-03-5 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-2,3-dihydro-3-[[(4-
methoxyphenyl)amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.



RN 422515-05-7 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-
piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA
INDEX
NAME)

Double bond geometry as shown.



RN 422515-07-9 CAPLUS
CN Benzenesulfonamide, 3-chloro-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-
piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA
INDEX
NAME)

Double bond geometry as shown.



RN 422515-09-1 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-
piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-4-methyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 422515-11-5 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-
piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-3-methyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 422515-13-7 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-
piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-3-methoxy- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 422515-15-9 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-
piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-4-methoxy- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 422515-17-1 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-2,4,6-trimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-19-3 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-4-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-21-7 CAPLUS
CN 2-Naphthalenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-30-8 CAPLUS
CN Benzenesulfonamide, 3-cyano-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-32-0 CAPLUS
CN Ethenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-2-phenyl-, (1E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-34-2 CAPLUS
CN 1H-Imidazole-4-sulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-1-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-24-0 CAPLUS
CN 8-Quinolinesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-26-2 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-28-4 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-2-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-36-4 CAPLUS
CN Benzenesulfonamide, 2-cyano-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-38-6 CAPLUS
CN 2-Pyridinesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-40-0 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-41-1 CAPLUS
CN Benzenemethanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-43-3 CAPLUS
CN 1-Propanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-45-5 CAPLUS
CN Benzenemethanesulfonamide, N-[(3Z)-3-[[[4-[[2-(dimethylamino)ethyl](methylsulfonyl)amino]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-47-7 CAPLUS
CN 2-Propanesulfonamide, N-[(3Z)-3-[[[4-[2-(dimethylamino)ethyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-50-2 CAPLUS
CN 1-Propanesulfonamide, N-[(3Z)-3-[[[4-[2-(dimethylamino)ethyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-52-4 CAPLUS
CN 1-Propanesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-[[methyl(phenylmethyl)amino]methyl]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-54-6 CAPLUS
CN Methanesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-[[methyl(phenylmethyl)amino]methyl]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-56-8 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-[[methyl(phenylmethyl)amino]methyl]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-58-0 CAPLUS
CN Benzenemethanesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-[[methyl(phenylmethyl)amino]methyl]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-60-4 CAPLUS
CN Benzenemethanesulfonamide, N-[(3Z)-3-[[[4-[2-(dimethylamino)ethyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-63-7 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[[4-[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]-3-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-65-9 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[[4-[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]-3-methoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-67-1 CAPLUS
CN Acetamide, N-[4-[[(Z)-(1,2-dihydro-5-[[(3-nitrophenyl)sulfonyl]amino]-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-69-3 CAPLUS
CN Acetamide, N-[4-[[(Z)-[1,2-dihydro-5-[[(2-nitrophenyl)sulfonyl]amino]-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-74-0 CAPLUS
CN Acetamide, N-[4-[[(Z)-[5-[[(3-cyanophenyl)sulfonyl]amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-76-2 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]-3-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-78-4 CAPLUS
CN 2-Pyridinesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-80-8 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-2-fluoro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-82-0 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-4-fluoro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-84-2 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-3-fluoro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-86-4 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]-2-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-88-6 CAPLUS
CN Benzenesulfonamide, 3-cyano-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-90-0 CAPLUS
CN Benzenesulfonamide, 2-cyano-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-91-1 CAPLUS
CN Benzeneacetic acid, 4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-93-3 CAPLUS
CN Benzeneacetic acid, 4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-95-5 CAPLUS
CN Benzeneacetamide, 4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-97-7 CAPLUS
CN Acetamide, 2-[[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl](methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422515-99-9 CAPLUS
CN Benzoic acid, 4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-01-6 CAPLUS
CN Benzoic acid, 4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-04-9 CAPLUS
CN Benzoic acid, 4-[[(Z)-[1,2-dihydro-5-[(methylsulfonyl)amino]-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-06-1 CAPLUS
CN Benzoic acid, 4-[[(Z)-[1,2-dihydro-5-[(methylsulfonyl)amino]-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-08-3 CAPLUS
CN Glycine, N-acetyl-N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-10-7 CAPLUS
CN Acetamide, N-(2-amino-2-oxoethyl)-N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-12-9 CAPLUS
CN Acetamide, N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-[2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-15-2 CAPLUS
CN Glycine, N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-(ethylsulfonyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-17-4 CAPLUS
CN Acetamide, 2-[[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-

indol-3-ylidene]phenylmethyl]amino]phenyl](ethylsulfonyl)amino]-N-[2-(dimethylamino)ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-19-6 CAPLUS
CN Acetamide, 2-[[4-[[(Z)-(1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl](ethylsulfonyl)amino]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-21-0 CAPLUS
CN Glycine,
N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-23-2 CAPLUS
CN Acetamide, 2-[[4-[[(Z)-(1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl](methylsulfonyl)amino]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-25-4 CAPLUS
CN Acetamide, 2-[[4-[[(Z)-(1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl](methylsulfonyl)amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-27-6 CAPLUS
CN Benzenesulfonamide,
N-[(3Z)-3-[[(4-aminophenyl)amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-30-1 CAPLUS
CN Benzenesulfonamide,
N-[(3Z)-3-[[[4-(aminomethyl)phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]-3-methoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-32-3 CAPLUS
CN Benzenemethanesulfonamide,
N-[(3Z)-3-[[[4-(aminomethyl)phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-34-5 CAPLUS
CN Benzenesulfonamide,
N-[(3Z)-3-[[[4-(aminomethyl)phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]-3-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-36-7 CAPLUS
CN Benzenesulfonamide,
N-[(3Z)-3-[[[4-[(ethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-38-9 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-[(propylamino)methyl]phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-40-3 CAPLUS
CN Benzenesulfonamide,
N-[(3Z)-3-[[[4-[(butylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-42-5 CAPLUS
CN Acetamide, N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-44-7 CAPLUS
CN Propanamide, N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-45-8 CAPLUS
CN Benzenesulfonamide, 3-(aminomethyl)-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



INDEX NAME)

Double bond geometry as shown.



RN 422516-56-1 CAPLUS
CN Benzenesulfonamide, 3-amino-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-58-3 CAPLUS
CN Benzenesulfonamide, 2-amino-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-60-7 CAPLUS
CN Benzenesulfonamide, 3-amino-N-[(3Z)-3-[[4-[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 422516-47-0 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[4-(aminomethyl)phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-49-2 CAPLUS
CN Benzenesulfonamide, 2-(aminomethyl)-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-51-6 CAPLUS
CN Acetamide, N-[4-[[(Z)-[5-[[[3-(aminomethyl)phenyl]sulfonyl]amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-53-8 CAPLUS
CN Benzenesulfonamide, 3-(aminomethyl)-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA



RN 422516-62-9 CAPLUS
CN Acetamide, N-[4-[[(Z)-[5-[[(3-aminophenyl)sulfonyl]amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-63-0 CAPLUS
CN Acetamide, N-[4-[[(Z)-[5-[[(2-aminophenyl)sulfonyl]amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-65-2 CAPLUS
CN Benzenesulfonamide, 3-amino-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-67-4 CAPLUS
CN Benzenesulfonamide, 3-amino-N-[(3Z)-3-[[[4-[(2,6-dimethyl-1-piperidinyl)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-69-6 CAPLUS
CN Benzenesulfonamide, 3-amino-N-[(3Z)-3-[[[4-(aminomethyl)phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-71-0 CAPLUS
CN Benzenesulfonamide, 3-amino-N-[(3Z)-2,3-dihydro-3-[[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-80-1 CAPLUS
CN Methanesulfonamide, N-[(3Z)-3-[[[4-[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-82-3 CAPLUS
CN 1-Propanesulfonamide, N-[(3Z)-3-[[[4-[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-84-5 CAPLUS
CN 1-Butanesulfonamide, N-[(3Z)-3-[[[4-[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-73-2 CAPLUS
CN Benzenesulfonamide, 2-amino-N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-pyrrolidinylmethyl)phenyl]amino]methylene]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-75-4 CAPLUS
CN Acetamide, N-[4-[[(Z)-[1,2-dihydro-5-[(methylsulfonyl)amino]-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-77-6 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[4-[[(Z)-[5-[(ethylsulfonyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-86-7 CAPLUS
CN Ethanesulfonamide, N-[(3Z)-3-[[[4-[(diethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-88-9 CAPLUS
CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[[(Z)-[5-[(ethylsulfonyl)amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-90-3 CAPLUS
CN 2-Pyridinesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 422516-92-5 CAPLUS
CN 2-Pyridinesulfonamide, N-[(3Z)-2,3-dihydro-3-[[[4-[[(2S)-2-hydroxy-1-pyrrolidinyl]methyl]phenyl]amino]phenylmethylene]-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 422516-94-7 CAPLUS
CN Acetamide, N-[4-[[(Z)-[1,2-dihydro-5-[methyl(phenylsulfonyl)amino]-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422516-96-9 CAPLUS
CN 1-Piperidineacetamide, N-[4-[[(Z)-[1,2-dihydro-5-[methyl(phenylsulfonyl)amino]-2-oxo-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 422556-77-2 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[[3-[[2-(dimethylamino)ethyl](methylsulfonyl)amino]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

Double bond geometry as shown.



RN 422516-98-1 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[[3-[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422517-00-8 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-3-[[[3-[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 422556-76-1 CAPLUS
CN Acetamide, N-(2-aminoethyl)-N-[4-[[(Z)-[1,2-dihydro-2-oxo-5-[(phenylsulfonyl)amino]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

ACCESSION NUMBER: 2001:167990 CAPLUS
DOCUMENT NUMBER: 134:222621
TITLE: Preparation of 3-anilinomethylidene-2-indolinones as kinase-mediated cell proliferation inhibitors
INVENTOR(S): Roth, Gerald Juergen; Heckel, Armin; Walter, Rainer; Tontsch-Grunt, Ulrike; Spevak, Walter; Van Meel, Jacobus C. A.
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016130	A1	20010308	WO 2000-EP8149	20000822
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19940829	A1	20010301	DE 1999-19940829	19990827
DE 10029285	A1	20011220	DE 2000-10029285	20000614
CA 2381821	AA	20010308	CA 2000-2381821	20000822
EP 1212318	A1	20020612	EP 2000-958481	20000822
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003508394	T2	20030304	JP 2001-519696	20000822
US 6794395	B1	20040921	US 2002-69557	20020722
US 2005009898	A1	20050113	US 2004-900162	20040727

PRIORITY APPLN. INFO.:
DE 1999-19940829 A 19990827
DE 2000-10029285 A 20000614
WO 2000-EP8149 W 20000822
US 2002-69557 A1 20020722

OTHER SOURCE(S): MARPAT 134:222621
GI



I

AB Title compds. [I; R = NR5R6; R1 = OH, cyano, (di)(alkyl)amino, alkoxy,

L5 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(hetero)aryl, etc.; R2 = H, halo, alkoxy, acyl, etc.; R3 = H, alkyl, Ph, etc.; R4 = H, alkyl, etc.; R5 = H or alkyl; R6 = (un)substituted Ph; X = O
or S) were prepd. Thus, 1-acetyl-5,6-dimethoxy-2-indolinone was condensed
with PhC(OEt)3 to give I (R1 = OMe, R2 = 5-OMe, R3 = Ph, X = O)(II; R = OEt, R4 = Ac) which was aminated by 4-(1-piperidinylmethyl)aniline (prepn.
given) to give, after deprotection, II [R = by 4-(1-piperidinylmethyl)anilino, R4 = H]. Data for biol. activity of I were given.

IT **328289-74-3P 328289-75-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-anilinomethylidene-2-indolinones as kinase-mediated cell
proliferation inhibitors)

RN 328289-74-3 CAPLUS
CN Methanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-6-yl]- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.



RN 328289-75-4 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-6-yl]- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:150592 CAPLUS
DOCUMENT NUMBER: 134:207710
TITLE: Preparation of 3-(anilinomethylidene)indoles as cell proliferation inhibitors
INVENTOR(S): Roth, Gerald Juergen; Heckel, Armin; Walter, Rainer; Tontsch-Grunt, Ulrike; Spevak, Walter; Van Meel, Jacobus
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: Ger. Offen., 32 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19940829	A1	20010301	DE 1999-19940829	19990827
CA 2381821	AA	20010308	CA 2000-2381821	20000822
WO 2001016130	A1	20010308	WO 2000-EP8149	20000822
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1212318	A1	20020612	EP 2000-958481	20000822
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003508394	T2	20030304	JP 2001-519696	20000822
US 6794395	B1	20040921	US 2002-69557	20020722
US 2005009898	A1	20050113	US 2004-900162	20040727

PRIORITY APPLN. INFO.:
DE 1999-19940829 A 19990827
DE 2000-10029285 A 20000614
WO 2000-EP8149 W 20000822
US 2002-69557 A1 20020722

OTHER SOURCE(S): MARPAT 134:207710
GI



AB Title compds. [I; R = NR5R6; R1 = OH, alkoxy, (hetero)aryl(alkyl), etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = H, alkyl, Ph, etc.; R4 = H, alkyl,

L5 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
etc.; R5 = H or alkyl; R6 = (un)substituted Ph; X = O or S] were prepd. Thus, 1-acetyl-5,6-dimethoxy-2-indolinone (prepn. given) was condensed with PhC(OEt)3 to give I (R1 = OMe, R2 = 5-OMe, R3 = Ph, X = O)(II; R = OEt, R4 = Ac) which was aminated by 4-(1-piperidinyl)aniline (prepn. given) to give, after N-deprotection, II [R = 4-(1-piperidinyl)anilino, R4
= H]. Data for biol. activity of I were given.

IT **328289-74-3P 328289-75-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(anilinomethylidene)indoles as cell proliferation inhibitors)

RN 328289-74-3 CAPLUS
CN Methanesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-6-yl]- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.



RN 328289-75-4 CAPLUS
CN Benzenesulfonamide, N-[(3Z)-2,3-dihydro-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indol-6-yl]- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.



L5 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:655644 CAPLUS
DOCUMENT NUMBER: 121:255644
TITLE: Indole derivatives as inhibitors of HIV reverse transcriptase
INVENTOR(S): Williams, Theresa M.; Ciccarone, Terrence M.; Saari, Walfred S.; Wai, John S.; Greenlee, William J.; Balani, Suresh K.; Goldman, Mark E.; Hoffman, Jacob M., Jr.; Lumma, William C., Jr.; et al.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA; Theoharides, Sharon, A.
SOURCE: PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9419321	A1	19940901	WO 1994-US1694	19940215
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2156420	AA	19940901	CA 1994-2156420	19940215
AU 9462542	A1	19940914	AU 1994-62542	19940215
BR 9405737	A	19951205	BR 1994-5737	19940215
EP 686148	A1	19951213	EP 1994-909663	19940215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1119856	A	19960403	CN 1994-191586	19940215
JP 08507067	T2	19960730	JP 1994-519119	19940215
HU 74614	A2	19970128	HU 1995-2468	19940215
PL 175788	B1	19990226	PL 1994-310410	19940215
US 5527819	A	19960618	US 1995-488957	19950607
FI 9503954	A	19950823	FI 1995-3954	19950823
NO 9503308	A	19951024	NO 1995-3308	19950823

PRIORITY APPLN. INFO.:
US 1993-21925 A 19930224
US 1991-756013 B2 19910906
US 1992-832260 B2 19920207
US 1992-866765 B2 19920409
WO 1994-US1694 W 19940215
US 1994-274101 B1 19940711

OTHER SOURCE(S): MARPAT 121:255644
GI



AB Novel indole compds. inhibit HIV reverse transcriptase (HIV RTR), and are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS. The described compds. include I [X = H, Cl, F, Br, NO2, cyano, OH, alkoxy, (di)(alkyl)amino, alkylamido, alkylsulfonamido; Y = S, SO, SO2, O; R = (un)substituted alkyl, aryl, heterocyclyl, dialkylamino (except when Y = O); Z = (un)substituted CONH2, CSNH2, alkanoyl, alkoxycarbonyl, aminomethyl, cyano, etc.; R' = H, CHO, acyl, (un)substituted CONH2] and their salts and esters. Approx. 180 I are prepared, listed, and/or claimed. For example, 5-chloroindole-2-carboxylic acid was treated with excess NaH in DMF and then with PhSSPh to give its 3-(phenylthio) derivative, which was amidated with 3-(aminomethyl)pyridine using BOP reagent and Et3N in DMF to give title compound II, a preferred compound I inhibited HIV RTR in vitro with IC50 of 3-35 nM for the most preferred compds. I also inhibited viral spread of HIV in cell cultures, with 95% inhibitory concns. (CIC95) of 3-400 nM for preferred compds.

IT 158561-75-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole derivs. as inhibitors of HIV reverse transcriptase)

RN 158561-75-2 CAPLUS

CN 1H-Indole-2-carboxamide, 5-[(methylsulfonyl)amino]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    67.81     239.72

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -9.75      -9.75

STN INTERNATIONAL LOGOFF AT 07:51:14 ON 24 JAN 2006
```

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☑ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☑ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning documents *will not* correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox